Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States
CNW Group - Tue Jul 29, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today announced the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, an application for Orphan Drug Designation for its Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory/relapsing high grade non-muscle invasive bladder cancer.
IIROC Trade Resumption - BNC
CNW Group - Fri Jul 18, 7:18AM CDT
Trading resumes in:
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States
CNW Group - Fri Jul 18, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today provided a key regulatory update on its flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory high grade non-muscle invasive bladder cancer.
IIROC Trading Halt - BNC
CNW Group - Thu Jul 17, 2:05PM CDT
The following issues have been halted by IIROC:
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
CNW Group - Fri Jun 13, 8:06AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"
Bioniche Provides Corporate Update
CNW Group - Tue Jun 03, 7:57AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today provided corporate updates on a number of key strategic initiatives including:
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast
CNW Group - Thu Mar 13, 5:06PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) today held a conference call and audio webcast for its shareholders, at which time, Company representatives provided several corporate updates. The corporate presentation used during today's call/webcast is available on the Company's website (www.Bioniche.com) under Investors - Corporate Presentations.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
CNW Group - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
CNW Group - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)